H. Vezina

发表

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

J. Machiels, G. Curigliano, A. Santoro, 2021, Clinical Cancer Research.

Antibody–Drug Conjugates: Clinical Strategies and Applications

H. Vezina, Lucy Lee, B. Schmidt, 2016 .

Nonclinical Pharmacology and Mechanistic Modeling of Antibody–Drug Conjugates in Support of Human Clinical Trials

H. Vezina, Huadong Sun, D. Leipold, 2016 .

A Randomized Crossover Study to Determine Bioequivalence of Generic and Brand Name Nevirapine, Zidovudine, and Lamivudine in HIV-Negative Women in India

H. Balfour, H. Vezina, D. Weller, 2006, Journal of acquired immune deficiency syndromes.

Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.

H. Balfour, K. Hogquist, H. Vezina, 2013, The Journal of infectious diseases.

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease

H. Balfour, H. Vezina, R. Brundage, 2009, Clinical pharmacology : advances and applications.

Valacyclovir Pharmacokinetics and Exploratory Pharmacodynamics in Young Adults With Epstein‐Barr Virus Infectious Mononucleosis

H. Balfour, H. Vezina, D. Weller, 2010, Journal of clinical pharmacology.

A method for evaluating antiviral drug susceptibility of Epstein-Barr virus

H. Balfour, H. Vezina, C. Holman, 2010 .

A virologic pilot study of valacyclovir in infectious mononucleosis.

H. Balfour, H. Vezina, R. Brundage, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Hybrid LBA/LC–MS TOP ARTICLES SUPPLEMENT

Huadong, Shrikant, Yan Zhang, 2016 .

Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography.

H. Balfour, H. Vezina, D. Weller, 2009, Biomedical chromatography : BMC.

PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?

J. Barrett, J. McGuire, S. Douglas, 2013, Journal of clinical psychopharmacology.

Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays.

T. Olah, Yan Zhang, H. Vezina, 2016, Bioanalysis.

An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study.

Robert J. Neely, S. Piccoli, H. Vezina, 2015, Bioanalysis.

Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.

H. Balfour, H. Vezina, R. Brundage, 2014, British journal of clinical pharmacology.

Model‐Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time‐Varying M Protein

H. Vezina, A. Roy, Y. Imai, 2020, Journal of clinical pharmacology.

An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

H. Balfour, H. Vezina, D. Weller, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

Jason Zhang, H. Vezina, P. Statkevich, 2019, CPT: pharmacometrics & systems pharmacology.

Antibody–Drug Conjugates as Cancer Therapeutics: Past, Present, and Future

M. Cotreau, H. Vezina, Manish Gupta, 2017, Journal of clinical pharmacology.

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

X. Zhao, S. Agrawal, S. Suryawanshi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models

Craig J. Thalhauser, H. Vezina, Yougan Cheng, 2017, The AAPS Journal.

CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20).

S. Dolfi, H. Vezina, I. Lugowska, 2021 .

Adjuvant therapies for HIV-associated neurocognitive disorders

J. Barrett, J. McGuire, S. Douglas, 2014, Annals of clinical and translational neurology.

Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors

J. Machiels, G. Curigliano, A. Santoro, 2019 .

Population Pharmacokinetics of Unbound Hydrocortisone in Critically Ill Neonates and Infants With Vasopressor-Resistant Hypotension

J. Barks, H. Vezina, V. Bhatt-Mehta, 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma

H. Vezina, M. Osawa, K. Sanghavi, 2021, Cancer Chemotherapy and Pharmacology.

QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models

Manish Gupta, Shepard Smithline, Craig J. Thalhauser, 2017, The AAPS Journal.

Article Type: Original Title: Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

X. Zhao, S. Agrawal, S. Suryawanshi, 2017 .

Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography.

H. Balfour, H. Vezina, D. Weller, 2009, Biomedical chromatography : BMC.